These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 33107920)

  • 1. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
    Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
    JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer.
    Abdel-Fatah TMA; Ball GR; Thangavelu PU; Reid LE; McCart Reed AE; Saunus JM; Duijf PHG; Simpson PT; Lakhani SR; Pongor L; Gyorffy B; Moseley PM; Green AR; Pockley AG; Caldas C; Ellis IO; Chan SYT
    JAMA Netw Open; 2020 Jul; 3(7):e209486. PubMed ID: 32633764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
    Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
    Huang L; Chen T; Chen C; Chen S; Liu Y; Wu J; Shao Z
    World J Surg Oncol; 2013 Nov; 11():307. PubMed ID: 24289519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
    Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.
    Huang O; Jiang M; Zhang X; Xie Z; Chen X; Wu J; Liu H; Shen K
    Jpn J Clin Oncol; 2013 Nov; 43(11):1064-72. PubMed ID: 24031083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.
    Abdel-Fatah TM; Ball G; Lee AH; Pinder S; MacMilan RD; Cornford E; Moseley PM; Silverman R; Price J; Latham B; Palmer D; Chan A; Ellis IO; Chan SY
    Clin Cancer Res; 2015 Mar; 21(5):1052-62. PubMed ID: 25520390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer.
    Khwaja SS; Ivanovich J; DeWees TA; Ochoa L; Mullen DF; Thomas M; Margenthaler JA; Cyr A; Naughton M; Sanati S; Eberlein TJ; Gillanders WE; Aft RL; Zoberi JE; Zoberi I
    Cancer Med; 2016 Feb; 5(2):230-8. PubMed ID: 26687192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.